Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366663 · ClinicalTrials.gov registry record · Phase 3
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
A Phase 3 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT02366663 is a Phase 3 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT02366663, a Phase 3 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
This randomized phase III trial studies 90-yttrium ibritumomab tiuxetan and combination chemotherapy compared with combination chemotherapy alone before stem cell transplant in treating patients with diffuse large b-cell non-Hodgkin lymphoma that has returned after a period of improvement. Radioactive substances linked to monoclonal antibodies, such as 90-yttrium ibritumomab tiuxetan, can bind to cancer cells and give off radiation which may help kill cancer cells. Drugs used in chemotherapy, such as carmustine, etoposide phosphate, cytarabine, and melphalan (BEAM), work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether 90-yttrium ibritumomab tiuxetan and BEAM before a stem cell transplant are more effective than BEAM alone in treating patients with diffuse large b-cell non-Hodgkin lymphoma.
Interventions
- DRUG Melphalan
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Carmustine
- RADIATION 90-Yttrium Ibritumomab tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02366663
The ClinicalTrials.gov registry entry for NCT02366663 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT02366663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02366663 about?
NCT02366663 is a clinical study titled "BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL". This randomized phase III trial studies 90-yttrium ibritumomab tiuxetan and combination chemotherapy compared with combination chemotherapy alone before stem cell transplant in treating patients with diffuse large b-cell non-Hodgkin lymphoma that has returned after a period of improvement. Radioacti...
What is the current status of trial NCT02366663?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2015-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02366663?
The interventions under investigation include: Melphalan (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Carmustine (DRUG), 90-Yttrium Ibritumomab tiuxetan (RADIATION).
Who is sponsoring clinical trial NCT02366663?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.